Influenza vaccines, also known as flu shots, are vaccines that protect against influenza. A new version of the vaccine is developed twice a year as the influenza virus rapidly changes. Most provide modest to high protection against influenza; however, each year this varies. Evidence in adults over 65 years old is poor. They decrease the number of missed days of work by a half day on average. Vaccinating children may protect those around them.
This report contains market size and forecasts of Human Injection Flu Vaccine in global, including the following market information:
Global Human Injection Flu Vaccine Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global Human Injection Flu Vaccine Market Sales, 2017-2022, 2023-2028, (Units)
Global top five Human Injection Flu Vaccine companies in 2021 (%)
The global Human Injection Flu Vaccine market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period 2022-2028.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Trivalent Influenza Vaccine Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Human Injection Flu Vaccine include Sanofi, CSL, GSK, Viatris, AstraZeneca, Hualan Bio, Changchun Institute of Biological, Sinovac and Jiangsu GDK and etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Human Injection Flu Vaccine manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Human Injection Flu Vaccine Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (Units)
Global Human Injection Flu Vaccine Market Segment Percentages, by Type, 2021 (%)
Trivalent Influenza Vaccine
Quadrivalent Influenza Vaccine
Global Human Injection Flu Vaccine Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (Units)
Global Human Injection Flu Vaccine Market Segment Percentages, by Application, 2021 (%)
6 Months to 3 Years
> 3 Years
Global Human Injection Flu Vaccine Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (Units)
Global Human Injection Flu Vaccine Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Human Injection Flu Vaccine revenues in global market, 2017-2022 (Estimated), ($ millions)
Key companies Human Injection Flu Vaccine revenues share in global market, 2021 (%)
Key companies Human Injection Flu Vaccine sales in global market, 2017-2022 (Estimated), (Units)
Key companies Human Injection Flu Vaccine sales share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Sanofi
CSL
GSK
Viatris
AstraZeneca
Hualan Bio
Changchun Institute of Biological
Sinovac
Jiangsu GDK
KM Biologics